High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib

Idiopathic Pulmonary Fibrosis Clinical Trial

— HOPE-IPF  

Official title:

High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02551068
• Other study ID #: H15-01200
• Status: Recruiting
• Phase: N/A
• Start date: December 2015
• Est. completion date: April 2025

Study information

• Verified date: November 2023
• Source: University of British Columbia
• Contact: Lynda Lazosky
• Phone: 604-682-2344
• Email: llazosky[@]providencehealth.bc.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose is to determine if patients with idiopathic pulmonary fibrosis (IPF) taking nintedanib will have improved exercise endurance, breathlessness and quality of life if breathing 60% oxygen compared to standard of care during an 8 week exercise training program.

Description:

Pulmonary rehabilitation is a structured evidence-based exercise and education intervention that is recommended for most patients with IPF. Pulmonary rehabilitation improves functional capacity (6-minute walk distance [6MWD]), breathlessness and quality of life in patients, however these benefits are often modest and only temporary. Nintedanib is an antifibrotic medication that has been shown to slow the decline of lung function. Use of antifibrotic medications in the pulmonary rehabilitation setting may therefore allow prolonged benefit of exercise training by preventing IPF progression and the resulting worsening symptoms and functional decline. Unpublished data suggest that breathing 60% oxygen in a pulmonary rehabilitation setting could enable patients to train at higher exercise intensities and thus derive greater physiological adaptations and clinical benefits compared with traditional pulmonary rehabilitation.

This is a randomized, blinded study with two arms (standard of care or 60% oxygen). The decision to start or stop treatment with nintedanib will be made by the participants treating physician based on clinical findings. If the treating physician decides to discontinue nintedanib, the participant will be allowed to continue in the study.

The exercise training program is 8 weeks long, with visits 3 times a week. In addition to the exercise training there are 13 visits occurring before, during and after the 8 week exercise training program. At study visits, participants will be required to conduct a 6 minute walk test and complete a quality of life questionnaire. Select study visits will also require lung function tests and exercise tests to be conducted.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 88
• Est. completion date: April 2025
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Age 19 years or older

• Idiopathic Pulmonary Fibrosis (IPF) diagnosis according to American Thoracic Society and/or European Respiratory Society consensus criteria

• Appropriate candidate for pulmonary rehabilitation

• prescribed nintedanib by their treating physician or currently on nintedanib

• 6 minute walk distance 50m or more

• Oxygen saturation 92% or more by pulse oximetry at rest while breathing room air

• Clinically stable for the preceding 6 weeks

Exclusion Criteria:

• Contraindication to treatment with nintedanib (based on Canadian labeling)

• Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)

• Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation

• Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%

• Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program

• Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit

• Use of pirfenidone within 4 weeks of screening

• Significant emphysema (less than 10% volume on high resolution computed tomography (HRCT) or forced expiratory volume at one second (FEV1)/FVC less than 0.70)

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Other:
• 60% Oxygen
While participants are exercising, they will be inhaling 60% oxygen through a mask
• Standard of Care
While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.

Locations

Country	Name	City	State
Canada	University of Calgary	Calgary	Alberta
Canada	University of Alberta	Edmonton	Alberta
Canada	McMaster University	Hamilton	Ontario
Canada	UBC Okanagan	Kelowna	British Columbia
Canada	Queens University	Kingston	Ontario
Canada	McGill University	Montreal	Quebec
Canada	Laval University	Quebec
Canada	St. Paul's Hospital	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
University of British Columbia	Boehringer Ingelheim

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in exercise duration during the constant load exercise test at 8 weeks	An constant load exercise test on a stationary bike will be performed. Patients will be told to exercise for as long as possible and endurance time will be defined as the duration of the constant load exercise test.	8 weeks
Secondary	Change in 6 Minute Walk Distance (6MWD) at 8 weeks	Patients will be asked to walk, at their own pace, as far as they can in 6 minutes.	8 weeks
Secondary	Change in the amount a patient is troubled by their breathlessness at 8 weeks	Measured using the modified Medical Research Council dyspnea scale (mMRC)	8 weeks
Secondary	Change in the amount a patient is troubled by their breathlessness during the 6 Minute Walk Distance test at 8 weeks	Measured using the 10-point Borg scale during 6MWD	8 weeks
Secondary	Change in the amount a patient is troubled by their breathlessness during the cycle exercise test at 8 weeks	Measured using the 10-point Borg scale during cycle exercise tests	8 weeks
Secondary	Change in how much shortness of breath the patient experiences while doing normal activities at 8 weeks	Measured using the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ).	8 weeks
Secondary	Change in the amount of physical work a patient can do before becoming breathless at 8 weeks	Measured using the oxygen cost diagram (OCD).	8 weeks
Secondary	Patient reported change in amount of physical activity at 8 weeks	Physical activity will be measured using the long form of the international physical activity questionnaire (IPAQ-LF).	8 weeks
Secondary	Change in amount of physical activity at 8 weeks	Physical activity will be measured objectively using the Fit Bit activity monitor.	8 weeks
Secondary	Change in Quality of Life at 8 weeks	Disease-specific quality of life will be measured using the St. George's Respiratory Questionnaire (SGRQ).	8 weeks